HANSOH PHARMA ANNOUNCES THE THIRD BIOLOGICS LICENSE APPLICATION OF XINYUE(INEBILIZUMAB INJECTION) ACCEPTED BY NMPA FOR THE TREATMENT OF GENERALIZED MYASTHENIA GRAVIS IN ADULT PATIENTS
On May, 30, 2025, Hansoh Pharmaceutical Group Co., Ltd. (Hansoh Pharma, 03692.HK) announces that Third Biologics License Application of XINYUE (Inebil...
2025.05.31